tiprankstipranks
Trending News
More News >

Marinus Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Marinus Pharmaceuticals (MRNS) to Neutral from Buy with a price target of $2, down from $11. The firm is “disappointed” after Marinus reported that ganaxolone failed in its pivotal trial to treat refractory TSC-associated seizures. This is the second significant setback for Marinus this year following the miss in refractory status epilepticus earlier in the spring, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue